triazolam has been researched along with Chemical Dependence in 56 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 53-year-old man with a 3-month addiction to approximately 5 mg/day of triazolam experienced psychosis and delirium following relatively abrupt withdrawal from the drug." | 7.67 | A case of psychosis and delirium following withdrawal from triazolam. ( Capwell, R; Heritch, AJ; Roy-Byrne, PP, 1987) |
| "In this study, we present five cases of seizures following withdrawal of flunitrazepam, lorazepam, or triazolam, representing 3% of a sample consisting of 153 patients dependent on benzodiazepines." | 3.69 | Benzodiazepine withdrawal syndrome seizures. ( de Iceta, M; Martínez-Cano, H; Martínez-Gras, I; Pomalima, R; Vela-Bueno, A, 1995) |
| "A 53-year-old man with a 3-month addiction to approximately 5 mg/day of triazolam experienced psychosis and delirium following relatively abrupt withdrawal from the drug." | 3.67 | A case of psychosis and delirium following withdrawal from triazolam. ( Capwell, R; Heritch, AJ; Roy-Byrne, PP, 1987) |
| "Meprobamate was indistinguishable from placebo on euphoria and abuse potential scales." | 2.71 | Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. ( Busto, UE; Greenblatt, DJ; Kaplan, HL; Sellers, EM; Zawertailo, LA, 2003) |
| "Triazolam was shown to be a reinforcer in four of the six subjects." | 2.68 | Reinforcing effects of triazolam in sedative abusers: correlation of drug liking and self-administration measures. ( Henningfield, JE; Jaffe, JH; Klein, S; Meisch, RA; Roache, JD; Sampson, A, 1995) |
| "Eight volunteers with histories of drug abuse participated in two experiments examining the modulation of drug choice by behavioral requirements following drug ingestion." | 2.67 | Modulation of drug reinforcement by behavioral requirements following drug ingestion. ( Griffiths, RR; Kirby, KC; Silverman, K, 1994) |
| " Six subjects received 80 mg DZ every third day (3 subjects) or every sixth day (3 subjects) for a total of 3-6 dosing occasions and six subjects received TZ (2." | 2.66 | Repeated administration of diazepam and triazolam to subjects with histories of drug abuse. ( Griffiths, RR; Roache, JD, 1986) |
| " The maximal dosage was 8 capsules per day (2." | 2.65 | Studies on the dependence-inducing potential of zopiclone and triazolam. ( Boissl, K; Delmotte, M; Dreyfus, JF, 1983) |
| " The maximal dosage was 8 capsules per day (2." | 2.65 | Studies on the dependence-inducing potential of zopiclone and triazolam. ( Boissl, K; Delmotte, M; Dreyfus, JF, 1982) |
| "Stupor is a diagnostic challenge at emergency department." | 1.48 | Segmental Hair Testing of Triazolam to Unmask a Suspected Case of Idiopathic Recurrent Stupor. ( Antelmi, E; Busardò, FP; Moresco, M; Pichini, S; Pizza, F; Plazzi, G; Postiglione, E, 2018) |
| "Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment." | 1.33 | Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. ( Griffiths, RR; Johnson, MW; Suess, PE, 2006) |
| " Flumazenil produced a mild or intermediate precipitated-withdrawal syndrome on day 14 of all dosing conditions." | 1.31 | Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. ( Ator, NA; Griffiths, RR; Kaminski, BJ; Kautz, MA; Weerts, EM, 2000) |
| "The present study investigates the effects of acute and chronic administration of triazolam in albino rats on glycine levels in different brain areas." | 1.31 | Brain glycine levels in triazolam-treated albino rats. ( Aburawi, SM; Ahmed, SS; Attia, AS; Elhwuegi, AS; Saad, SF, 2001) |
| "Imidazenil has a longer half-life than an equipotent dose of diazepam and protects rats against bicuculline-induced convulsions for a significantly longer time than diazepam or bretazenil." | 1.29 | Imidazenil, a partial positive allosteric modulator of GABAA receptors, exhibits low tolerance and dependence liabilities in the rat. ( Auta, J; Costa, E; Giusti, P; Guidotti, A, 1994) |
| "Triazolam was the single drug most frequently used by high-dose dependents, followed by Lorazepam." | 1.29 | Benzodiazepine types in high versus therapeutic dose dependence. ( De Iceta, M; Martínez-Cano, H; Martínez-Gras, I; Pomalima, R; Sobrino, MP; Vela-Bueno, A, 1996) |
| " We report five cases of high-dose triazolam abuse in which the daily dosage ranged from 5 to 15 mg (100-300 mg diazepam equivalent) and the duration of use ranged from 3 months to 5 years." | 1.28 | Detoxification for triazolam physical dependence. ( Sellers, EM; Sullivan, JT, 1992) |
| "treatment with alprazolam induced clear physical dependence in DBA/2J mice as assessed by precipitation of a withdrawal syndrome with an i." | 1.28 | Physical dependence induced in DBA/2J mice by benzodiazepine receptor full agonists, but not by the partial agonist Ro 16-6028. ( Haefely, WE; Jenck, F; Martin, JR; Moreau, JL; Pieri, L; Schoch, P, 1990) |
| " During chronic administration of brotizolam, triazolam and diazepam all animals gained body weight." | 1.27 | Physical dependence capacity of brotizolam in rhesus monkeys. 2nd communication: primary dependence and barbital substitution. ( Stockhaus, K, 1986) |
| " In naive animals, after the chronic administration of midazolam at 0." | 1.27 | [Drug dependence tests on a new anesthesia inducer, midazolam]. ( Hakkei, M; Kubota, A; Kuwahara, A; Nakamura, K, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (42.86) | 18.7374 |
| 1990's | 20 (35.71) | 18.2507 |
| 2000's | 10 (17.86) | 29.6817 |
| 2010's | 1 (1.79) | 24.3611 |
| 2020's | 1 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Kriikku, P | 1 |
| Rasanen, I | 1 |
| Ojanperä, I | 1 |
| Thelander, G | 1 |
| Kronstrand, R | 1 |
| Vikingsson, S | 1 |
| Postiglione, E | 1 |
| Antelmi, E | 1 |
| Moresco, M | 1 |
| Pichini, S | 1 |
| Pizza, F | 1 |
| Plazzi, G | 1 |
| Busardò, FP | 1 |
| Zawertailo, LA | 1 |
| Busto, UE | 1 |
| Kaplan, HL | 1 |
| Greenblatt, DJ | 1 |
| Sellers, EM | 2 |
| Weerts, EM | 2 |
| Ator, NA | 8 |
| Kaminski, BJ | 2 |
| Griffiths, RR | 22 |
| Mintzer, MZ | 3 |
| Johnson, MW | 1 |
| Suess, PE | 2 |
| Carter, LP | 1 |
| Casada, JH | 1 |
| Wallace, CL | 1 |
| Roache, JD | 9 |
| Fleming, JA | 1 |
| Boissl, K | 2 |
| Dreyfus, JF | 2 |
| Delmotte, M | 2 |
| Bechelli, LP | 1 |
| Navas, F | 1 |
| Pierangelo, SA | 1 |
| Lukas, SE | 1 |
| Lamb, RJ | 4 |
| Brady, JV | 4 |
| Cumin, R | 1 |
| Bonetti, EP | 1 |
| Scherschlicht, R | 1 |
| Haefely, WE | 2 |
| Woods, JH | 1 |
| Winger, G | 1 |
| Meisch, RA | 1 |
| Henningfield, JE | 1 |
| Jaffe, JH | 1 |
| Klein, S | 1 |
| Sampson, A | 1 |
| Silverman, K | 1 |
| Kirby, KC | 1 |
| Cohen, C | 1 |
| Sanger, DJ | 1 |
| Rush, CR | 2 |
| Higgins, ST | 2 |
| Hughes, JR | 2 |
| Bickel, WK | 2 |
| Auta, J | 1 |
| Giusti, P | 1 |
| Guidotti, A | 1 |
| Costa, E | 1 |
| Martínez-Cano, H | 3 |
| Vela-Bueno, A | 4 |
| de Iceta, M | 2 |
| Pomalima, R | 2 |
| Martínez-Gras, I | 2 |
| Sobrino, MP | 1 |
| Baker, RW | 1 |
| Wright, K | 1 |
| Marc, B | 1 |
| Baudry, F | 1 |
| Vaquero, P | 1 |
| Zerrouki, L | 1 |
| Hassnaoui, S | 1 |
| Douceron, H | 1 |
| Kautz, MA | 1 |
| Allen, RP | 1 |
| Aburawi, SM | 1 |
| Ahmed, SS | 1 |
| Elhwuegi, AS | 1 |
| Saad, SF | 1 |
| Attia, AS | 1 |
| Toyo'oka, T | 1 |
| Kanbori, M | 1 |
| Kumaki, Y | 1 |
| Nakahara, Y | 1 |
| Sannerud, CA | 1 |
| Sullivan, JT | 1 |
| Green, S | 1 |
| Goldberg, D | 1 |
| Frischer, M | 1 |
| McKeganey, N | 1 |
| Evans, SM | 3 |
| Critchfield, TS | 1 |
| Moreau, JL | 1 |
| Jenck, F | 1 |
| Pieri, L | 1 |
| Schoch, P | 1 |
| Martin, JR | 1 |
| Funderburk, FR | 1 |
| Piot, O | 1 |
| Betschart, J | 1 |
| Stutzmann, JM | 1 |
| Blanchard, JC | 1 |
| Tan, TL | 1 |
| Bixler, EO | 2 |
| Kales, A | 2 |
| Cadieux, RJ | 1 |
| Goodman, AL | 1 |
| Lynn, EJ | 1 |
| Albeck, JH | 1 |
| Lamb, R | 1 |
| Bigelow, GE | 1 |
| Heritch, AJ | 1 |
| Capwell, R | 1 |
| Roy-Byrne, PP | 1 |
| Stockhaus, K | 1 |
| Kubota, A | 1 |
| Kuwahara, A | 1 |
| Hakkei, M | 1 |
| Nakamura, K | 1 |
| Soldatos, CR | 1 |
| Singh, AN | 1 |
| Chemij, M | 1 |
| Jewell, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Randomized, Single Center, Double-Blind, Multiple-Dose, Placebo-Controlled, Crossover, Double-Dummy Study of The Acute Behavioral and Subjective Effects of Ramelteon in Subjects With a History of Polydrug Abuse.[NCT00671632] | Phase 2 | 14 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia[NCT03075657] | Phase 4 | 120 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
4 reviews available for triazolam and Chemical Dependence
| Article | Year |
|---|---|
Current benzodiazepine issues.
Topics: Age Factors; Benzodiazepines; Humans; Memory Disorders; Risk Factors; Substance Withdrawal Syndrome; | 1995 |
Relative abuse liability of triazolam: experimental assessment in animals and humans.
Topics: Amnesia; Animals; Anti-Anxiety Agents; Behavior, Animal; Discrimination, Psychological; Drug Interac | 1985 |
Withdrawal and detoxification from benzodiazepine dependence: a potential role for clonazepam.
Topics: Adolescent; Adult; Aged; Alprazolam; Anti-Anxiety Agents; Clonazepam; Diazepam; Drug Tolerance; Huma | 1987 |
Behavioral side effects of benzodiazepine hypnotics.
Topics: Amnesia; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Flurazepam; Humans; Hypnotics and Sedatives; | 1985 |
16 trials available for triazolam and Chemical Dependence
| Article | Year |
|---|---|
Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
Topics: Adult; Analysis of Variance; Barbiturates; Behavior, Addictive; Dose-Response Relationship, Drug; Fe | 2003 |
An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers.
Topics: Adult; Anti-Anxiety Agents; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Doub | 2005 |
Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects.
Topics: Adult; Behavior; Benzodiazepines; Cognition; Dose-Response Relationship, Drug; Female; Humans; Hypno | 2007 |
Studies on the dependence-inducing potential of zopiclone and triazolam.
Topics: Adult; Anti-Anxiety Agents; Azabicyclo Compounds; Blood Pressure; Body Temperature; Double-Blind Met | 1983 |
Studies on the dependence-inducing potential of zopiclone and triazolam.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Azabicyclo Compounds; Double-Blind Method; Humans; Hypnotics | 1982 |
Reinforcing effects of triazolam in sedative abusers: correlation of drug liking and self-administration measures.
Topics: Adult; Anxiety; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypnotics and Sedativ | 1995 |
Modulation of drug reinforcement by behavioral requirements following drug ingestion.
Topics: Adult; Arousal; Behavior; Dextroamphetamine; Double-Blind Method; Environment; Humans; Male; Reinfor | 1994 |
A comparison of the acute behavioral effects of triazolam and temazepam in normal volunteers.
Topics: Adult; Behavior; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; | 1993 |
Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability.
Topics: Adult; Anti-Anxiety Agents; Arousal; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 1998 |
Investigation of preference for nightly triazolam versus placebo in moderate social alcohol drinkers.
Topics: Adult; Alcohol Drinking; Double-Blind Method; Humans; Hypnotics and Sedatives; Male; Reinforcement, | 2001 |
Abuse liability assessment of anxiolytics/hypnotics: rationale and laboratory lore.
Topics: Anti-Anxiety Agents; Dose-Response Relationship, Drug; Humans; Hypnotics and Sedatives; Pyridines; R | 1991 |
Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.
Topics: Adult; Behavior; Cognition; Dose-Response Relationship, Drug; Humans; Male; Psychomotor Performance; | 1990 |
Diazepam and triazolam self-administration in sedative abusers: concordance of subject ratings, performance and drug self-administration.
Topics: Adult; Diazepam; Double-Blind Method; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychomoto | 1989 |
Zolpidem and triazolam in humans: behavioral effects and abuse liability.
Topics: Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypnotics and Sedatives; Men | 1989 |
Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability.
Topics: Adult; Analysis of Variance; Anti-Anxiety Agents; Cognition; Dose-Response Relationship, Drug; Human | 1985 |
Repeated administration of diazepam and triazolam to subjects with histories of drug abuse.
Topics: Adult; Diazepam; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Male; Psychomotor Perform | 1986 |
36 other studies available for triazolam and Chemical Dependence
| Article | Year |
|---|---|
Femoral blood concentrations of flualprazolam in 33 postmortem cases.
Topics: Accidents; Adolescent; Adult; Age Distribution; Aged; Benzodiazepines; Designer Drugs; Female; Finla | 2020 |
Segmental Hair Testing of Triazolam to Unmask a Suspected Case of Idiopathic Recurrent Stupor.
Topics: Adult; Hair; Humans; Male; Recurrence; Stupor; Substance-Related Disorders; Time Factors; Triazolam | 2018 |
Comparison of the behavioral effects of bretazenil and flumazenil in triazolam-dependent and non-dependent baboons.
Topics: Animals; Behavior, Animal; Benzodiazepinones; Dose-Response Relationship, Drug; Eating; Flumazenil; | 2005 |
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Topics: Administration, Oral; Adult; Cognition; Cross-Over Studies; Dose-Response Relationship, Drug; Double | 2006 |
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Topics: Administration, Oral; Adult; Cognition; Cross-Over Studies; Dose-Response Relationship, Drug; Double | 2006 |
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Topics: Administration, Oral; Adult; Cognition; Cross-Over Studies; Dose-Response Relationship, Drug; Double | 2006 |
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Topics: Administration, Oral; Adult; Cognition; Cross-Over Studies; Dose-Response Relationship, Drug; Double | 2006 |
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Topics: Administration, Oral; Adult; Cognition; Cross-Over Studies; Dose-Response Relationship, Drug; Double | 2006 |
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Topics: Administration, Oral; Adult; Cognition; Cross-Over Studies; Dose-Response Relationship, Drug; Double | 2006 |
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Topics: Administration, Oral; Adult; Cognition; Cross-Over Studies; Dose-Response Relationship, Drug; Double | 2006 |
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Topics: Administration, Oral; Adult; Cognition; Cross-Over Studies; Dose-Response Relationship, Drug; Double | 2006 |
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Topics: Administration, Oral; Adult; Cognition; Cross-Over Studies; Dose-Response Relationship, Drug; Double | 2006 |
Triazolam abuse.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Humans; Male; Sleep Initiation and Maintenance Disorders; Su | 1983 |
Comparison of the reinforcing properties of zopiclone and triazolam in former alcoholics.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Azabicyclo Compounds; Capsules; Double-Blind Method; Electro | 1982 |
Benzodiazepines: drug discrimination and physiological dependence.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Benzodiazepines; Bromazepam; Diazepam; Discrimination Lear | 1984 |
Experimental assessment of the relative abuse liability of triazolam and pentobarbital.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Pentobarbital; Psychomot | 1984 |
Use of the specific benzodiazepine antagonist, Ro 15-1788, in studies of physiological dependence on benzodiazepines.
Topics: Animals; Benzodiazepines; Benzodiazepinones; Cats; Diazepam; Female; Flumazenil; Humans; Lorazepam; | 1982 |
Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines.
Topics: Benzodiazepines; Chlordiazepoxide; Clorazepate Dipotassium; Diazepam; Flurazepam; Humans; Lorazepam; | 1980 |
Tolerance, cross-tolerance and dependence measured by operant responding in rats treated with triazolam via osmotic pumps.
Topics: Animals; Anti-Anxiety Agents; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Toleranc | 1994 |
Imidazenil, a partial positive allosteric modulator of GABAA receptors, exhibits low tolerance and dependence liabilities in the rat.
Topics: Allosteric Regulation; Animals; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Brain; Diazepam | 1994 |
Daytime consumption of triazolam.
Topics: Adult; Aged; Anxiety; Circadian Rhythm; Drug Tolerance; Female; Humans; Male; Middle Aged; Self Medi | 1993 |
Benzodiazepine withdrawal syndrome seizures.
Topics: Adult; Anti-Anxiety Agents; Female; Flunitrazepam; Heroin Dependence; Humans; Hypnotics and Sedative | 1995 |
Benzodiazepine types in high versus therapeutic dose dependence.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Cross-Sectional Studies; Dose-Response Relation | 1996 |
Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans.
Topics: Adult; Antidepressive Agents, Tricyclic; Humans; Hypnotics and Sedatives; Male; Memory; Mental Recal | 1999 |
Sexual assault under benzodiazepine submission in a Paris suburb.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Cocaine; Dronabinol; Estazolam; Female; Flu | 2000 |
Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons.
Topics: Acetamides; Animals; Dose-Response Relationship, Drug; GABA Modulators; Hypnotics and Sedatives; Mal | 2000 |
Brain glycine levels in triazolam-treated albino rats.
Topics: Animals; Anti-Anxiety Agents; Brain; Brain Chemistry; Dose-Response Relationship, Drug; Drug Adminis | 2001 |
Determination of triazolam involving its hydroxy metabolites in hair shaft and hair root by reversed-phase liquid chromatography with electrospray ionization mass spectrometry and application to human hair analysis.
Topics: Aged; Animals; Anti-Anxiety Agents; Chromatography, High Pressure Liquid; Hair; Humans; Male; Mass S | 2001 |
Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal.
Topics: Animals; Barbiturates; Cocaine; Discrimination Learning; Drug Tolerance; Hypnotics and Sedatives; Ma | 1992 |
Detoxification for triazolam physical dependence.
Topics: Adult; Alcoholism; Diazepam; Dose-Response Relationship, Drug; Female; Half-Life; Hospitalization; H | 1992 |
Triazolam as a substance of abuse among injecting drug users.
Topics: Comorbidity; Female; Humans; Male; Substance Abuse Treatment Centers; Substance Abuse, Intravenous; | 1992 |
Oral self-administration of triazolam, diazepam and ethanol in the baboon: drug reinforcement and benzodiazepine physical dependence.
Topics: Animals; Conditioning, Operant; Diazepam; Drinking Behavior; Ethanol; Flumazenil; Food; Half-Life; M | 1992 |
Physical dependence induced in DBA/2J mice by benzodiazepine receptor full agonists, but not by the partial agonist Ro 16-6028.
Topics: Administration, Oral; Alprazolam; Animals; Anti-Anxiety Agents; Benzodiazepinones; Diazepam; Drug Im | 1990 |
Development of repeated acquisition methodologies: implications for the detection of drug-induced disruption in human learning.
Topics: Dose-Response Relationship, Drug; Humans; Illicit Drugs; Mental Recall; Neuropsychological Tests; Oc | 1990 |
Cyclopyrrolones, unlike some benzodiazepines, do not induce physical dependence in mice.
Topics: Animals; Azabicyclo Compounds; Carbolines; Convulsants; Diazepam; Disease Models, Animal; Flunitraze | 1990 |
Effects of repeated RO 15-1788 administration in benzodiazepine-dependent baboons.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepinones; Convulsants; Diazepam; Drug Tolerance; Flumazenil; | 1985 |
Early morning insomnia, daytime anxiety, and organic mental disorder associated with triazolam.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Humans; Male; Sleep Initiation and Maintenance Disorders; Subst | 1985 |
Triazolam addiction.
Topics: Adult; Anti-Anxiety Agents; Diazepam; Humans; Male; Substance Withdrawal Syndrome; Substance-Related | 1985 |
Progress report from the Division of Behavioral Biology, the Johns Hopkins University School of Medicine.
Topics: Animals; Drug Tolerance; Humans; Male; Maryland; Papio; Pentobarbital; Research; Self Administration | 1986 |
A case of psychosis and delirium following withdrawal from triazolam.
Topics: Delirium; Humans; Lorazepam; Male; Middle Aged; Psychoses, Substance-Induced; Substance Withdrawal S | 1987 |
Physical dependence capacity of brotizolam in rhesus monkeys. 2nd communication: primary dependence and barbital substitution.
Topics: Animals; Azepines; Barbital; Barbiturates; Body Weight; Diazepam; Female; Hypnotics and Sedatives; M | 1986 |
[Drug dependence tests on a new anesthesia inducer, midazolam].
Topics: Animals; Injections, Intravenous; Macaca fascicularis; Male; Midazolam; Pentobarbital; Self Administ | 1986 |
Abuse liability of triazolam: experimental measurements in animals and humans.
Topics: Animals; Diazepam; Drug Tolerance; Humans; Male; Papio; Pentobarbital; Psychomotor Performance; Self | 1987 |
Treatment of triazolam dependence with a tapering withdrawal regimen.
Topics: Adult; Humans; Male; Placebos; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Fact | 1986 |